Exelixis, Inc. $EXEL Shares Sold by Skandinaviska Enskilda Banken AB publ

Skandinaviska Enskilda Banken AB publ lessened its stake in Exelixis, Inc. (NASDAQ:EXEL) by 85.6% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 2,112 shares of the biotechnology company’s stock after selling 12,600 shares during the quarter. Skandinaviska Enskilda Banken AB publ’s holdings in Exelixis were worth $87,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Denali Advisors LLC raised its holdings in Exelixis by 7.9% in the third quarter. Denali Advisors LLC now owns 10,922 shares of the biotechnology company’s stock valued at $451,000 after acquiring an additional 800 shares in the last quarter. State of New Jersey Common Pension Fund D increased its position in shares of Exelixis by 6.0% in the 3rd quarter. State of New Jersey Common Pension Fund D now owns 92,473 shares of the biotechnology company’s stock valued at $3,819,000 after purchasing an additional 5,198 shares during the last quarter. HighTower Advisors LLC increased its position in shares of Exelixis by 22.2% in the 3rd quarter. HighTower Advisors LLC now owns 87,228 shares of the biotechnology company’s stock valued at $3,603,000 after purchasing an additional 15,846 shares during the last quarter. BTC Capital Management Inc. raised its holdings in shares of Exelixis by 10.5% in the 3rd quarter. BTC Capital Management Inc. now owns 11,195 shares of the biotechnology company’s stock valued at $462,000 after purchasing an additional 1,063 shares in the last quarter. Finally, Abich Financial Wealth Management LLC purchased a new stake in shares of Exelixis during the 3rd quarter worth $47,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Exelixis

In related news, Director Jack L. Wyszomierski sold 99,574 shares of the firm’s stock in a transaction dated Wednesday, February 18th. The stock was sold at an average price of $44.01, for a total transaction of $4,382,251.74. Following the transaction, the director owned 279,942 shares of the company’s stock, valued at $12,320,247.42. This trade represents a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Bob Oliver sold 30,250 shares of the stock in a transaction that occurred on Friday, February 13th. The stock was sold at an average price of $43.81, for a total value of $1,325,252.50. Following the sale, the director directly owned 21,120 shares of the company’s stock, valued at $925,267.20. The trade was a 58.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 285,058 shares of company stock valued at $12,460,245. Corporate insiders own 2.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on EXEL shares. Zacks Research raised Exelixis from a “hold” rating to a “strong-buy” rating in a report on Wednesday, February 4th. Wells Fargo & Company upped their price objective on Exelixis from $30.00 to $35.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 11th. UBS Group set a $41.00 price objective on Exelixis in a report on Monday, January 5th. TD Cowen reissued a “buy” rating on shares of Exelixis in a research report on Wednesday, November 5th. Finally, Barclays upped their price target on Exelixis from $41.00 to $44.00 and gave the company an “equal weight” rating in a report on Wednesday, February 4th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, Exelixis presently has an average rating of “Hold” and an average target price of $47.11.

Exelixis Trading Down 1.2%

EXEL stock opened at $43.63 on Monday. The company has a market capitalization of $11.33 billion, a P/E ratio of 15.75, a PEG ratio of 0.98 and a beta of 0.42. The business has a 50 day simple moving average of $43.88 and a 200-day simple moving average of $41.25. Exelixis, Inc. has a twelve month low of $32.38 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL) last released its quarterly earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 EPS for the quarter, beating the consensus estimate of $0.74 by $0.20. The firm had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a net margin of 33.73% and a return on equity of 36.29%. Exelixis’s revenue for the quarter was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.55 EPS. Research analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.